Cocrystal Pharma, Inc. COCP
1.02 USD -0.01 (-0.97%)
At closeNov 11, 2026, 4:00 PM EST
1.03 +0.01 +0.98%
After hours · Nov 11, 4:00 PM ET
1.00 Day range 1.05
0.76 52-week range 2.03
- YTD
- +4.08%
- 1 year
- -9.73%
News
defenseworld.net Cocrystal Pharma (NASDAQ:COCP) Shares Cross Above 200-Day Moving Average – What’s Next? Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.10 and traded as high as…
defenseworld.net Xeris Biopharma (NASDAQ:XERS) vs. Cocrystal Pharma (NASDAQ:COCP) Head-To-Head Contrast Cocrystal Pharma (NASDAQ: COCP - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare…
globenewswire.com Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash.
globenewswire.com Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet…
benzinga.com Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000K Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.17) by 43.75 percent. This is a 15 percent decrease over losses of…
benzinga.com Cocrystal Pharma Secures $5M Investment From OPKO Health To Advance Norovirus Program Toward Phase 1b Data Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.…
globenewswire.com Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.…
defenseworld.net Financial Contrast: Cocrystal Pharma (NASDAQ:COCP) vs. Zevra Therapeutics (NASDAQ:ZVRA) Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cocrystal Pharma (NASDAQ: COCP - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will…
globenewswire.com Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer BOTHELL, Wash. , June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet…
benzinga.com Watching Cocrystal Pharma; Zacks-Small Cap Research Gives Stock $8 Price Valuation https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_06012026_COCP_Bautz.pdf- benzinga.com Cocrystal Pharma's Direct-Acting Antivirals Demonstrate Pan-Viral Activity Against Multiple Viruses, Including Hantavirus, Bunyavirus And Influenza Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenzaHantavirus and bunyavirus infections…
globenewswire.com Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenza Hantavirus and bunyavirus infections…
benzinga.com Cocrystal Pharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $225.000K Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 26.09 percent increase over losses of…
globenewswire.com Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides updates on its antiviral product pipeline and business activities and…
benzinga.com Cocrystal Pharma Features Mechanism Of Action And Clinical Advancement Of Oral Protease Inhibitor CDI-988 In Oral Presentation At 39th ICAR 2026 Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatmentFully enrolled first cohort is assessing…
globenewswire.com Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the mechanism of action and clinical advancement of its first…
benzinga.com Cocrystal Pharma Files $150M Shelf Offering To Sell Stock, Warrants, And Other Securities $150,000,000 Cocrystal Pharma, Inc. Common StockPreferred StockWarrantsUnits Cocrystal Pharma, Inc. ("Cocrystal," the "Company," "we," "our," or "us") intends to offer and sell from time to time the
benzinga.com Why Cocrystal Pharma Shares Are Cooling Off Monday? COCP stock is trading lower Monday morning. Learn why Cocrystal Pharma is seeing a pullback after receiving FDA Fast Track designation for CDI-988.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Quarry Inc. and Cocrystal Pharma Inc. shares increase.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Nasdaq Down 1%; US Initial Jobless Claims Fall US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer discretionary stocks fell. US jobless claims declined.
benzinga.com Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988 The company said the FDA's Fast Track designation is intended to facilitate development and expedite regulatory review for drugs that treat serious conditions and address unmet medical needs.
benzinga.com Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988 Cocrystal Pharma Inc. (NASDAQ:COCP) shares are trading higher Thursday after it received Fast Track designation from the FDA for its CDI-988.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Cocrystal Pharma Says FDA Grants Fast Track Designation To Its Direct-Acting Protease Inhibitor, CDI-988, Oral Antiviral Candidate Being Developed For Treatment And Prophylaxis Of Norovirus Infection FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion…
globenewswire.com Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion…
benzinga.com Cocrystal Pharma Q4 EPS $(0.17) Beats $(0.21) Estimate Cocrystal Pharma (NASDAQ:COCP) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 46.88 percent increase over losses of…
globenewswire.com Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs Phase 1b norovirus challenge study is underway at Emory University School of Medicine CDI-988 is the first oral antiviral candidate being developed for norovirus treatment and prevention No approved…
defenseworld.net Cocrystal Pharma (COCP) Expected to Announce Earnings on Monday Cocrystal Pharma (NASDAQ: COCP - Get Free Report) is anticipated to issue its results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.18) per…
defenseworld.net Cocrystal Pharma (NASDAQ:COCP) Shares Up 2% – Should You Buy? Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report)'s stock price traded up 2% during mid-day trading on Monday. The stock traded as high as $1.0338 and last traded at $1.03. 48,239 shares…
globenewswire.com First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No…
globenewswire.com Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that initial progress of a norovirus challenge study with its…
defenseworld.net Insider Buying: Cocrystal Pharma (NASDAQ:COCP) Director Buys $19,400.00 in Stock Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report) Director Phillip Md Et Al Frost bought 20,000 shares of Cocrystal Pharma stock in a transaction on Tuesday, December 30th. The stock was…
globenewswire.com Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the approval from the Institutional Review Board (IRB) at Emory…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com US Stocks Open Higher; House Prices Increase In October - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 258 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 325 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday OnFriday, 143 stocks hit new 52-week lows.
- benzinga.com Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
- benzinga.com Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.